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Implantable peritoneal portAbstract Purpose: To evaluate the safety and efﬁciency of percutaneous implantable peritoneal
port in minimally invasive treatment of intractable ascites.
Patients and methods: 40 patients with malignant ascites were referred from the oncology clinic to
the radiodiagnosis department for percutaneous placement of peritoneal port catheter as a palliative
treatment under guidance of ultrasonography and ﬂuoroscopy. Ports were evaluated for safety and
efﬁciency.
Results: The technical insertion success rate of percutaneous implantable peritoneal port was
100% with gradual removal of ascites together with 100% immediate relief of symptoms. No major
complication was noticed however one minor immediate complication (2.5%) was detected as
leakage at the port placement site which stopped spontaneously with removal of ascites and conser-
vative patient management .In long term results, one patient (2.5%) developed infection at port site
after 3 months of successful ascites drainage. This technique avoided ascites related morbidity,
increases patient compliance, and satisfaction by decreasing hospital visits as the drainage and
patients monitor can be done at home.
Conclusion: The percutaneous implantable peritoneal port system is safe and effective in palliation
of symptomatic malignant ascites with minimal invasive treatment. Port aspiration can be per-
formed by patients or family members without nursing assistance or hospital visits.
 2014 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Radiology and Nuclear
Medicine. Open access under CC BY-NC-ND license.1. Introduction
Ascites is a common complication of advanced malignancies
and cirrhosis (1–3). It usually carries a poor prognosis in both
cancer and liver disease (4,5). The commonest causes of malig-
nant ascites are primary tumor of breast, ovary, colon, stom-
ach, pancreas and bronchus (6).
Symptoms of ascites include marked abdominal distention,
shortness of breath, diminished appetite, fatigue, and
418 M.K. Abdel Ghaffar et al.lower-extremity edema which can signiﬁcantly compromise a
patient’s everyday function (2).
Diuretics have long been a useful treatment in cirrhotic
ascites (7) and liver metastasis ascites (8,9). However they
can cause electrolyte disturbance and hypotension, so they
need to be used with caution in patient with poor renal or
hepatic function (10).
Available treatment options for intractable ascites include
repeated paracentesis, transjugular portosystemic shunt
(TIPS) creation, peritoneovenous shunting, liver transplanta-
tion (11,12). Tunneled peritoneal catheters with external com-
ponent which was not considered viable treatment options as
a result of problems with infection, malposition, and occlu-
sion (11,12); however, they have been used for many years
for peritoneal dialysis with acceptable complication rates
(13,14). In 1999, 27,000 people received peritoneal dialysis
in the United States, constituting 9% of the dialysis popula-
tion, where mortality rates was similar to or lower than those
in hemodialysis patients (15). Tunneled catheters have gener-
ally been placed in operating rooms (13). Recently, 2-year
catheter survival rates with percutaneous placement have been
reported to be 49–82% (15). Rosenblum et al. (11) described
the use of a subcutaneous venous access port to treat refrac-
tory ascites with promising results in 9 patients.
Recently peritoneal port represents minimally invasive
effective option for treatment of intractable ascites (11,12).2. The aim of the work
The purpose of this study was to evaluate prospectively the
safety and effectiveness of radiologically placed peritoneal
ports in palliation of malignant ascites.Fig. 1 Peritoneal implantable port with a 14.3F silicone catheter
(Bard Access System, Inc., Salt Lake City, UT, USA).3. Patients and methods
3.1. Patients
This prospective interventional study included 40 patients (25
male and 15 female, mean age 58.1) with malignant ascites
referred from the oncology clinic to the radiodiagnosis depart-
ment at Ain Shams University Specialized Hospitals for percu-
taneous placement of peritoneal port catheter as a palliative
treatment between October 2010 and March 2013.
3.2. Inclusion and exclusion criteria
Patients included in our study were selected according to the
following criteria:
o International normalizing ratio (INR) less than 1.5.
o Prothrombin time should be less than 15 s.
o Partial thromboplastin time should be near normal.
o Platelet count should be greater than 50,000 per mm3 to
limit the risk of bleeding.
o There should be no infection at the time of port placement.
o At least a moderate amount of ascites should be present at
the time of port placement to help insure placement of the
catheter in an optimal location.
o No age predilection.
o Patients with infected ascites were excluded.The selected patients who had approved to participate in
our study gave an informed consent (or their guardians ap-
proved) their images will be included.
3.3. Procedure
The standard retrograde procedure of peritoneal implantable
port with a 14.3F silicone catheter (Bard Access System,
Inc., Salt Lake City, UT, USA) (Fig. 1) to the patients was
as follows:
Ultrasonography was used to mark the puncture site of large
volume ascites without loculations and an 18G Chiba needle
was used for ultrasound (US) guided puncture. An appropriate
insertion site at the right lower quadrant was locally anesthe-
tized with Prilocaine HCl. After the stylet of the needle was re-
moved, spontaneous drainage of uncomplicated ascites was
conﬁrmed. A 0.035-in guide wire was advanced into the pelvic
aspect of the peritoneal cavity under ﬂuoroscopy and a 6F dila-
tor was inserted over the guide wire, which was then removed
and a dilator was capped.
The port pocket was created 5–8 cm (tunnel length) above
the puncture site over the anterolateral lower ribs. A 3–4 cm
incision was made and a subcutaneous pocket was prepared
according to the reservoir size. The thickness of the tissues be-
tween the port pocket and the skin was approximately 1 cm to
permit easily location of reservoir by palpation and to prevent
skin necrosis.
A subcutaneous tunnel was created between the pocket and
the ascites. The reservoir end of the catheter was connected to
the tunneler, pulled through the tunnel, cut to the appropriate
length and connected to the reservoir. It was placed into the
pocket and ﬁxed to skin with a 19G Huber needle (Fig. 2).
The guide wire was advanced to the pelvic portion of the per-
itoneal cavity through the dilator under ﬂuoroscopy guidance
and serial dilatation was performed. A 16F peel-away sheath
was placed over the guide wire and the catheter was advanced
Fig. 2 Pocket and peritoneal entry site. The port pocket was
prepared over the anterolateral lower ribs (straight arrow). Needle
holder at the ascites entry site (curved arrow).
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removed.
Port-catheter function and integrity were conﬁrmed with
sterile saline injection and ascites aspiration via Huber needle.
Theportsitewasclosedwithtwolayersofsubcutaneous3–0Vi-
cryl(EthiconInc.)absorbablesutures.Theportwasaccessedwitha
25largebore19GHuberneedleforhigherﬂowinashortertimeafter
preparationwitha sterile technique.Thepatientswere advised to
aspirate a maximum volume of 3 L to avoid volume depletion.
Theport-catheterwasﬂushedwith20 mLofheparinizedsalinesolu-
tion(2000 IUheparin,100 IU/mL)aftereachuse.
3.4. Data were collected and evaluated as regard the following
points
1. Procedural data included immediate results: Technical suc-
cess of port placement, removal of ascites, symptoms relief,
and immediate complications.
2. Long-term follow-up data included long term results:Duration
of symptom relief, requirement for port removal, duration of
port patency, location where port aspiration was performed
(hospital visits), and long term complications.0%
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Fig. 3 Chart showing short term results.4. Results
Our study was performed with the participation of 40 patients
between October 2010 and March 2013, comprising 25 males
(age range from 45 to 71 years old, mean age 60.2) and 15 fe-
males (age range from 32 to 68 years old, mean age 54.5).
Themale patients included 5 patientswith cancer colon, 5 pa-
tients with mesothelioma, 5 patients with cancer head of pan-
creas, 4 patients with bronchogenic carcinoma, 3 patients with
cancer sigmoid and 3 patients with cancer stomach.
The female patients included 3 patients with cancer stomach,
3 patients with cancer sigmoid, 6 patients with cancer ovary, 1
patient with uterine liomyosarcoma, 1 patient with mesotheli-
oma, and 1 patient with adenosarcoma.
4.1. Data were collected and evaluated as regard the following
points
4.1.1. Immediate results (Fig. 3)
Forty ports were placed in 40 patients which all show technical
success in insertion with removal of ascites gradually andimmediate relief of symptoms. There were no major complica-
tions. There was one minor complication, which was a leakage
at the port placement site in a patient with pancreatic carci-
noma and this stopped spontaneously with removal of ascites
and patient conservative management.
4.1.2. Long-term results (Fig. 4)
Thirty-nine patients (97.5%) showed complete relief of symp-
toms and good compliance until death. The ports were still
in place and functioning at the time of death or till the end
of this study (Fig. 5).
Thirty-nine patients (97.5%) were treated successfully with-
out further catheter manipulation (catheter removal), or anti-
biotic therapy.
One patient (2.5%) had an unsuccessful procedure. She had
her port successfully inserted (technical success) followed by
immediate relief of symptoms and decreased hospital visits
yet three month later she developed infection at port site and
loculation of ascites. Ascites sampling, culture and sensitivity
were performed where Escherichia coli single growth was
discovered. Cather removal and aggressive antibiotic were pre-
scribed after which infection subsided with no reaccumulation
of ascites till the end of this study.
Two patients (5%) had kinking (Fig. 6) and migration of
the catheter in the subphrenic region 3 months after the proce-
dure. Yet it was still well functioning.
The long-term patency rate of ports was 100% with mean
patency duration 284.5 days. Forty patients were treated with
peritoneal port without any occlusion that did not respond to a
20-ml of heparinized saline solution ﬂush.
Twenty-eight patients died during the course of the study
due to severity of their underlying disease. Among whom,
the patency rate was 100%, with complete relief of symptoms
in all.
Twelve patients survived till the end of the study with pa-
tency rate 100%, and all had complete relief of symptoms
caused by ascites.
Thirty patients (75%) were treated at home (with decreased
hospital visits) and ﬁve (12.5%) were treated as outpatients in
our clinic because they were not able to use the device. Five pa-
tients (12.5%) were admitted to the hospital because of other
medical problems (Fig. 7).
Avoidance of repeated paracentesis was satisfactory to
patients and clinicians.
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Fig. 4 Chart showing long term results.
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Intractable large-volume ascites is often disabling. It decreases
and compromises the quality of the patients’ life. It may be due
to cirrhotic liver or malignant ascites (16).
The goal of management of malignant ascites is the effec-
tive relief of symptoms in the safest and most convenient man-
ner for the patient. Treatment options include: repeated
paracentesis, tunneled peritoneal catheters, TIPS, peritoneove-
nous shunting, peritoneogastric shunt, peritoneal-urinary
drainage and peritoneal portcatheters. Some of the previously
listed techniques require repeated hospital visits. Others are
invasive techniques that require general anesthesia (3). They
also carry high risk of infection and bleeding, can be compli-
cated by encephalopathy, disseminated intravascular coagula-
tion or early occlusion (17).
Cuffed, tunneled percutaneously placed peritoneal ports
series were ﬁrst described by Rosenblum et al. in 2001 (11).
It was modiﬁed venous access ports with one reported case
of catheter obstruction (10% of catheters). In the study per-
formed by Ozkan (16) and in our study, we used peritoneal
port speciﬁcally designed to permit repeated access to the per-
itoneal cavity. Compared with the device used by Rosenblum
et al., this catheter is larger in caliber and has multiple side
holes (Fig. 1). These properties may explain the 100% patency
rate in both studies.
There are 2 general types of tunneled peritoneal ports: ante-
grade or retrograde tunneled lines. The antegrade tunneledFig. 5 65 years old female patient with metastatic cancer stomach. Cl
clear tense ascites. (a) Axial CT scan shows port-catheter in place sub
place in the pelvic cavity (white arrow).catheter must be measured and cut to the correct length before
threading the tunneler and catheter from superior incision
(catheter exit site) to incision at the insertion site through the
subcutaneous tunnel. With retrograde tunneling, the tip of
the catheter and the tunneler were threaded from the insertion
site to incision at catheter exit site. In our study we agreed with
Rosenblum et al. (11), Savin et al. (1) and Ozkhan et al. (16)
for the use of the retrograde technique as we assumed that this
will help placing the catheter in a good pelvic position allowing
better drainage with high technical success rate.
Previously port pocket was created related to the anterior
superior iliac spine (11). In a study by Ozkan et al. (16), the
placement of the port was over a bony surface (lower costal
margin) yet the reservoir reversed on the ﬁrst day of the proce-
dure due to the large pocket size without suturing the port. In
our study, a 3–4 cm incision was made and a subcutaneous
pocket was prepared according to the reservoir size at the low-
er costal margin and the port was sutured. This explained the
absence of reservoir reversal and provided an easier target for
nurses or family members to access the port.
During our study we were not confronted by hematoma at
the port placement site as reported by Savin et al. (1), or by
extensive ecchymosis at the reservoir and tunnel site resulting
in patient discomfort and difﬁculty in port access for the ﬁrst
few aspiration as reported by Monsky et al. (18).
Savin et al. (1), reported that they had one patient whose
port was placed the day after paracentesis and loculated ascites
was not recognized at the time of placement, likely because of
the presence of only minimal residual ascites at the time of port
placement. Because the catheter was placed into a loculated
collection, the patient required additional paracenteses to
maintain symptom relief. In our study, ultrasonography was
used to mark the puncture site of large volume ascites without
loculations.
We agreed with Ozkan et al. (16), that the kinking and
migration of the catheter in the subdiaphragmatic region did
not cause any problems or affected the drainage.
Spontaneous bacterial peritonitis is much more common in
patients with ascites with underlying cirrhosis than in patients
with malignancies (19). Spontaneous bacterial peritonitis oc-
curs in 8–10% of patients with cirrhotic ascites, but only a rare
case report has described spontaneous bacterial peritonitis in
patients with cancer with ascites (20). O’Neill et al. (2) haveinical examination and radiological studies were done. US revealed
cutaneously (white arrow). (b) CT shows port-catheter catheter in
Fig. 6 59 years old female patient diagnosed as liomyosarcoma
of the uterus. Clinical examination and radiological studies were
done. US revealed clear tense ascites. 3 months later, radiograph
revealed a kinked subphrenic port-catheter (black arrow).
Fig. 7 Pie chart showing hospital visit distribution.
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with a tunneled peritoneal catheter that was placed under
sonographic and ﬂuoroscopic guidance; of whom 4 patients
(17%) developed bacterial peritonitis, three of them responded
to antibiotics and one had to have his catheter removed. In our
study we reported low infection rate only in one case (2.5%)
which occurred 3 month after successful insertion and use of
the port. Infection was attributed to inability of the patient
to use the port under aseptic conditions so the port was
removed.
Monsky et al. (18), were confronted with three cases with
leaking of peritoneal ﬂuid from the catheter entry site in pa-
tients of obese body habitus and two with ﬁndings suggestive
of cellulitic skin irritation. Rosenblum et al. (11) reported that
two of three cases of peritonitis were associated with peritoneal
ﬂuid leakage at the port site with gap in port incision. They
suggested that these infections could have been prevented with
improved suture technique and its removal 10–14 days after
port placement. In our study, the port site was closed with
two layers of subcutaneous 3–0 Vicryl (Ethicon Inc.) invertedsutures, and the skin is closed by interrupted silk sutures.
The leakage at the port placement site was noticed in one pa-
tient with pancreatic carcinoma and this stopped spontane-
ously with removal of ascites and patient adequate
conservative management.
In our study, the technical success rate and the long term
patency were 100% and the efﬁcacy rate of the port catheter
was 97.5%.
6. Conclusion
Peritoneal port system for intractable ascites is a safe and an
efﬁcient way to avoid morbidity and the patient’s anxiety re-
lated to marked ascites with repeated puncture-aspiration. It
provides a closed system between tapping sessions where it al-
lows an entire integration with total liberty in daily life be-
tween two sessions of drainage which can be performed at
home. It has a minimal rate of complication. This patient-
friendly technique may be a treatment option with good suc-
cess rate, patient compliance and clinician satisfaction.Conﬂict of interest
None.
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